September 12, 2011
Astellas Pharma announced on September 5 that it entered into a license agreement on the same day with Evec, a Hokkaido-based bioventure, for an investigational fully-human antibody against infectious diseases. Under the terms of the agreement, Astellas will obtain worldwide...read more